The European Medicines Agency proposed draft rules to fast‑track clinical trial approvals during declared public health emergencies, encouraging sponsors to coordinate with the EMA’s Emergency Task Force and prioritizing well‑designed multicenter trials over fragmented compassionate use. The guidance outlines flexibilities for site transfers and adapted procedures while underscoring the need to protect participant safety and data integrity. In the U.S., the FDA moved to widen the labeled use of leucovorin for a rare cerebral folate deficiency condition without new trial data, citing literature and mechanistic evidence. The agency’s action and the EMA’s draft guidance both reflect regulatory trendlines toward pragmatic, evidence‑focused flexibility in crises and in rare diseases, while also raising questions about evidentiary thresholds and implementation details for sponsors and clinicians. Named sources: European Medicines Agency draft guidance and U.S. FDA label decision on leucovorin. For clarity: these regulatory moves affect trial timing, design, and off‑label versus labeled availability in emergency and rare‑disease settings.